FDA Approved: IDHIFA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA approved a supplemental application for IDHIFA (enasidenib mesylate) from Celgene, updating the labeling and/or expanding its indication for IDH2-mutate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

SUPPL AP for IDHIFA (ENASIDENIB MESYLATE)